AbCellera Biologics (ABCL) Resumen de Acciones
AbCellera Biologics Inc. se dedica a descubrir y desarrollar medicamentos basados en anticuerpos para indicaciones con necesidades médicas no cubiertas en Estados Unidos. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 0/6 |
| Crecimiento futuro | 1/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 6/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
ABCL Community Fair Values
Create NarrativeSee what 99 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de AbCellera Biologics Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$5.80 |
| Máximo en las últimas 52 semanas | US$8.44 |
| Mínimo de 52 semanas | US$2.75 |
| Beta | 1.15 |
| Cambio en 1 mes | 4.88% |
| Variación en 3 meses | 45.36% |
| Cambio de 1 año | 12.62% |
| Variación en 3 años | -24.18% |
| Variación en 5 años | -62.31% |
| Variación desde la OPV | -90.15% |
Noticias y actualizaciones recientes
Actualización de narrativa • Jul 09
ABCL: Jazz Deal And Menopause Program Will Support A Stronger Outlook
The analyst fair value estimate for AbCellera Biologics has been raised from $12.00 to $13.00 as analysts point to the new Jazz Pharmaceuticals agreement, recent rating upgrades, and a more constructive view on the company's long term earnings potential, despite lower modeled revenue growth and a higher future P/E assumption. Analyst Commentary Bullish analysts covering AbCellera Biologics are highlighting the recent agreement with Jazz Pharmaceuticals as an important proof point for the company’s partnership model and revenue opportunity.
Actualización de narrativa • Jun 25
ABCL: Menopause Phase 2 Progress Will Shape Future Upside Potential
Analysts have lifted their price target on AbCellera Biologics by $1, citing recent bullish coverage and views that the company’s profile compares favorably with certain peers as key reasons for the change. Analyst Commentary Recent research on AbCellera Biologics points to a generally positive tone, with several bullish initiations and a modest price target increase that together shape how analysts are thinking about the stock’s valuation, growth potential, and execution risks.Recent updates
Actualización de narrativa • Jul 09
ABCL: Jazz Deal And Menopause Program Will Support A Stronger Outlook
The analyst fair value estimate for AbCellera Biologics has been raised from $12.00 to $13.00 as analysts point to the new Jazz Pharmaceuticals agreement, recent rating upgrades, and a more constructive view on the company's long term earnings potential, despite lower modeled revenue growth and a higher future P/E assumption. Analyst Commentary Bullish analysts covering AbCellera Biologics are highlighting the recent agreement with Jazz Pharmaceuticals as an important proof point for the company’s partnership model and revenue opportunity.Actualización de narrativa • Jun 25
ABCL: Menopause Phase 2 Progress Will Shape Future Upside Potential
Analysts have lifted their price target on AbCellera Biologics by $1, citing recent bullish coverage and views that the company’s profile compares favorably with certain peers as key reasons for the change. Analyst Commentary Recent research on AbCellera Biologics points to a generally positive tone, with several bullish initiations and a modest price target increase that together shape how analysts are thinking about the stock’s valuation, growth potential, and execution risks.Seeking Alpha • Jun 17
AbCellera: An AI-Era Antibody Platform Trading For Little More Than Its Cash
Summary AbCellera, an antibody platform behind two authorized COVID-19 therapies, has rebuilt itself into a clinical-stage biotech and is one quarter away from pivotal Phase 2 data on its first wholly-owned. The deeper story is the platform: an integrated, AI-driven discovery engine that mines millions of immune cells rather than designing molecules from scratch, backed by a decade of proprietary wet lab. With more than $650M in liquidity against a roughly $1.6B market cap, investors are paying little more than cash and effectively getting the platform, the pipeline, and ~100 royalty positions. I initiate my coverage of AbCellera with a “Buy” rating, viewing it as an asymmetric, catalyst-driven bet for investors who can tolerate binary risk. Read the full article on Seeking AlphaActualización de narrativa • Jun 10
ABCL: Menopause Phase 2 Progress Will Support Future Margin Expansion
The analyst price target on AbCellera Biologics has been raised by $1. Analysts cite updated fair value estimates, a slightly lower discount rate, revised revenue growth expectations, and a very large projected future P/E multiple as key drivers of the change.
Actualización de narrativa • May 26
ABCL: GPCR Platform Progress And Upcoming Women’s Health Data Will Drive Upside
Analysts lifted their price target on AbCellera Biologics by $1, citing recent bullish initiations and research that view the company’s profile as increasingly attractive relative to selected peers. Analyst Commentary Recent Street research on AbCellera Biologics highlights a mix of optimism and caution, with several firms updating their views and price targets in light of the company’s current positioning and peer comparisons.Artículo de análisis • May 14
Earnings Update: Here's Why Analysts Just Lifted Their AbCellera Biologics Inc. (NASDAQ:ABCL) Price Target To US$10.14
AbCellera Biologics Inc. ( NASDAQ:ABCL ) investors will be delighted, with the company turning in some strong numbers...Actualización de narrativa • May 06
ABCL: Platform And Partnerships Will Support Future Upside From GPCR Pipeline Progress
The analyst price target for AbCellera Biologics has shifted to $7.00, with analysts pointing to updated assumptions around the discount rate, revenue growth, profit margins, and a very large future P/E multiple. This view is supported by recent bullish Street coverage that frames the company as increasingly attractive relative to certain peers.Actualización de narrativa • Apr 20
ABCL: Platform And Partnerships Will Support Future Upside Potential
Analysts have adjusted their price target on AbCellera Biologics to $7.00. The change reflects updated assumptions around revenue trends, profit margins, discount rates, and future P/E, supported by recent research that takes a bullish view on the stock.Actualización de narrativa • Apr 06
ABCL: Menopause Phase 2 Progress Will Support Future Upside Potential
Analysts maintained their $7.00 price target for AbCellera Biologics, citing only very small adjustments to assumptions around discount rate, revenue trends, profit margin, and future P/E as the basis for keeping their overall valuation view steady. What's in the News AbCellera Biologics has started dosing patients in the Phase 2 portion of its ongoing Phase 1/2 clinical trial for ABCL635, a potential first in class non hormonal treatment for moderate to severe vasomotor symptoms associated with menopause (Key Developments).Actualización de narrativa • Mar 22
ABCL: Menopause Trial Progress Will Drive Future Share Price Upside
Analysts have trimmed their price targets on AbCellera Biologics to $7.00, citing updated assumptions for revenue growth, profit margins and a higher future P/E multiple that together point to a more cautious outlook on how quickly the business may scale. What's in the News First patients have been dosed in the Phase 2 portion of AbCellera's ongoing Phase 1/2 clinical trial for ABCL635, a potential first in class non hormonal treatment for moderate to severe vasomotor symptoms associated with menopause (Key Developments).Actualización de narrativa • Mar 08
ABCL: Patent Settlement And Menopause Trial Will Support A Stronger Outlook
Analysts have lowered their price target on AbCellera Biologics from $15.88 to $12.00, reflecting updated views on fair value, revenue growth expectations, and future P/E assumptions. What's in the News The first patients have been dosed in the Phase 2 portion of AbCellera's ongoing Phase 1/2 clinical trial for ABCL635, a potential first in class non hormonal treatment for moderate to severe vasomotor symptoms associated with menopause (Key Developments).Actualización de narrativa • Feb 22
ABCL: Menopause Phase 2 Progress And Bruker Settlement Will Support Future Margins
Analysts have maintained their $9.83 price target on AbCellera Biologics, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E, which they view as collectively balanced at this stage. What's in the News AbCellera began dosing patients in the Phase 2 portion of its ongoing Phase 1/2 trial for ABCL635, a potential first in class non hormonal treatment for moderate to severe vasomotor symptoms associated with menopause.Actualización de narrativa • Feb 08
ABCL: Clinical Progress And Royalty Deal Will Drive Future Share Price Upside
Analysts have reduced their price target on AbCellera Biologics, citing updated assumptions that incorporate higher expected revenue growth and profit margins, partially offset by a lower projected future P/E multiple. What's in the News First patients have been dosed in the Phase 2 portion of AbCellera's ongoing Phase 1/2 clinical trial for ABCL635, a potential first in class non hormonal treatment for moderate to severe vasomotor symptoms associated with menopause.Actualización de narrativa • Jan 24
ABCL: Phase 2 Menopause Trial Progress Will Support Future Profit Margins
Analysts have trimmed their price target on AbCellera Biologics to US$9.83, reflecting slightly lower discount rate assumptions, a modestly higher long term profit margin outlook, and a small adjustment to future P/E expectations. What's in the News First patients have been dosed in the Phase 2 portion of AbCellera's ongoing Phase 1/2 clinical trial for ABCL635, a potential first in class non hormonal treatment for moderate to severe vasomotor symptoms associated with menopause.Actualización de narrativa • Jan 08
ABCL: Patent Settlement Cash Flows Will Support A Stronger Future Outlook
Analysts have trimmed their implied fair value estimate for AbCellera Biologics from about US$17.00 to roughly US$15.88, reflecting updated assumptions around discount rates, revenue growth, profit margins, and future P/E levels. What's in the News AbCellera reached a global settlement and patent license agreement with Bruker Corporation, resolving ongoing patent litigation between the two companies (Key Developments).Actualización de narrativa • Dec 14
ABCL: Higher Future Earnings Multiple Will Drive Strong Share Price Upside
Analysts have raised their price target on AbCellera Biologics by approximately 40 percent to reflect a higher fair value estimate of around 7 dollars per share. They cite expectations for modestly slower revenue growth, offset by improved profit margins and a richer future earnings multiple.Actualización de narrativa • Nov 29
ABCL: Upcoming Clinical Trial Results Will Drive Future Profit Margins Higher
Analysts have adjusted their price target for AbCellera Biologics slightly downward from $10.20 to $9.83 per share. This change reflects more conservative expectations around future revenue growth and profit margins.Actualización de narrativa • Nov 15
ABCL: Upcoming Clinical Trial Results Are Expected To Drive Profit Margins Higher
Analysts have raised their price target for AbCellera Biologics from $9.33 to $10.20 per share, citing improved profit margin forecasts even though revenue growth expectations have slightly moderated. What's in the News AbCellera Biologics has begun dosing the first participants in a Phase 1 clinical trial for ABCL575, an investigational antibody therapy aimed at treating moderate to severe atopic dermatitis with potential applications in other inflammatory and autoimmune conditions (Key Developments).Nueva narrativa • May 18
Phase I Trials And Manufacturing Will Unlock Pipeline Potential
Transition to a clinical-stage biotech and internal programs could drive revenue through milestone fees and royalty payments from new molecules.Artículo de análisis • May 15
Some Analysts Just Cut Their AbCellera Biologics Inc. (NASDAQ:ABCL) Estimates
The latest analyst coverage could presage a bad day for AbCellera Biologics Inc. ( NASDAQ:ABCL ), with the analysts...Seeking Alpha • Apr 17
AbCellera: Attractively Priced But A Catalyst Is Needed
Summary AbCellera's stock remains under pressure due to a shift towards internal development, which has reduced revenue and increased cash burn. AbCellera retains a large cash position, though, giving it a multi-year runway in which to demonstrate the merits of its platform. AbCellera's low enterprise value suggests that investors are either skeptical of the company's platform or ignoring its cash position. A more favorable macro environment and clinical success will likely be needed before AbCellera's stock moves meaningfully higher. Read the full article on Seeking AlphaSeeking Alpha • Mar 15
AbCellera: Burning Cash, Searching For 'Blockbusters'
Summary AbCellera's revenues plummeted post-COVID antiviral sales, leading to a significant net loss and an 85% drop in share price, now at ~$2.5. The company is pivoting to develop its own drug pipeline, with ABCL635 and ABCL575 in late-preclinical stages, targeting metabolic and inflammatory conditions. Financially, AbCellera has ~$840 million in liquidity, but its market cap is lower than its cash reserves, reflecting skepticism about its assets. The company's future hinges on successfully developing a blockbuster drug, with key catalysts not expected until 2026, making its current valuation a gamble. Read the full article on Seeking AlphaSeeking Alpha • Dec 23
AbCellera Biologics: Still A Concept Stock
Summary Today, we revisit a somewhat unique developmental company called AbCellera Biologics Inc. The company is moving towards focusing more on its wholly owned candidates off its platform rather than partnerships. The company has myriad very early-stage assets in development, and ABCL stock trades near the net cash on its balance sheet. An updated analysis around AbCellera Biologics follows in the paragraphs below. Read the full article on Seeking AlphaArtículo de análisis • Nov 07
AbCellera Biologics Inc. (NASDAQ:ABCL) Just Reported And Analysts Have Been Cutting Their Estimates
It's shaping up to be a tough period for AbCellera Biologics Inc. ( NASDAQ:ABCL ), which a week ago released some...Seeking Alpha • Oct 14
AbCellera: A Platform To Pipeline Transition
Summary AbCellera is shifting its focus from a platform biotech company to its internal drug pipeline. The company's lead asset, ABCL575, comes with a variety of risks, but in our opinion, has a value of a little over $1B and is derisked based on comparable therapeutics. AbCellera is on track to submit ABCL575 for clinical trials in Q22025, helping the market reset its valuation on the company closer to the value of the lead asset. Read the full article on Seeking AlphaSeeking Alpha • Aug 23
AbCellera: A Waiting Game With High Uncertainty
Summary AbCellera’s Q2 2024 revenue declined by 27% year-over-year to $7.3 million. The company’s net loss widened to $36.9 million due to increased R&D expenses. AbCellera’s cash and marketable securities totaled $697.6 million, with total liquidity exceeding $900 million. The number of molecules in clinical trials increased from nine to 14 within a year. A "hold" recommendation is maintained due to the speculative and high-risk nature of AbCellera’s business. Read the full article on Seeking AlphaArtículo de análisis • May 29
Companies Like AbCellera Biologics (NASDAQ:ABCL) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Seeking Alpha • May 16
AbCellera: Cash Providing Shelter From Market Weakness
Summary AbCellera Biologics is a drug discovery company focused on developing antibody therapies. While the company has developed a technology platform that is open to customers, the current market environment has accelerated its shift towards advancing internal programs. This move should allow the company to capture more value in the long run, but it is depressing revenue and increasing cash burn at the moment. AbCellera's large cash balance will safely see it through this current period, but financial conditions will likely need to ease for the stock to rebound. Read the full article on Seeking AlphaSeeking Alpha • Feb 28
AbCellera: Victim Of Its Own Success
Summary AbCellera Biologics has faced declining royalty revenues, along with decreased demand for R&D services due to the current financing environment. As a result, AbCellera is shifting focus towards advancing internal programs and partner programs with more potential downstream value. The combination of declining revenue and rising costs is pressuring the stock, even as the underlying business appears to be steadily progressing. This situation appears to have been exacerbated by the company's success during the pandemic leading to over-inflated investor expectations, and subsequently, disappointment. Read the full article on Seeking AlphaSeeking Alpha • Feb 13
AbCellera Biologics: Continuing To Expand Partnerships
Summary AbCellera Biologics Inc. saw a significant decline in revenue due to the end of the COVID-19 pandemic, but has a large cash hoard and continues to expand partnerships. Analyst firms continue to Buy/Outperform ratings on the stock, but the company's partner pipeline is primarily very early-stage candidates. An updated analysis around AbCellera Biologics follows in the paragraphs below. Read the full article on Seeking AlphaRentabilidad de los accionistas
| ABCL | US Life Sciences | Mercado US | |
|---|---|---|---|
| 7D | -11.0% | -1.3% | -1.4% |
| 1Y | 12.6% | 24.4% | 17.1% |
Rentabilidad vs. Industria: Los resultados de ABCL fueron inferiores a los de la industria US Life Sciences, que obtuvo un rendimiento del 24.4% el año pasado.
Rentabilidad vs. Mercado: ABCL obtuvo unos resultados inferiores a los del mercado US, que fueron del 17.1% el año pasado.
Volatilidad de los precios
| ABCL volatility | |
|---|---|
| ABCL Average Weekly Movement | 13.5% |
| Life Sciences Industry Average Movement | 9.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.2% |
Precio estable de las acciones: El precio de las acciones de ABCL ha sido volátil durante los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de ABCL(13%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de US.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2012 | 562 | Carl Hansen | www.abcellera.com |
AbCellera Biologics Inc. se dedica al descubrimiento y desarrollo de medicamentos basados en anticuerpos para indicaciones con necesidades médicas no cubiertas en Estados Unidos. Su producto estrella es el ABCL635, un medicamento no hormonal que se encuentra en fase 2 de ensayo clínico para el tratamiento de los síntomas vasomotores de moderados a graves; y el ABCL575, un anticuerpo monoclonal totalmente humano con vida media prolongada, que se encuentra en un ensayo clínico de fase I para el tratamiento de enfermedades autoinmunes mediadas por células T, como la dermatitis atópica. La empresa tiene un acuerdo de colaboración en investigación y licencia con Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc para desarrollar anticuerpos multiespecíficos que interactúan con las células T (TCE); y un acuerdo de colaboración con Viking Global Investors & ArrowMark Partners y Biogen Inc. AbCellera Biologics Inc. se constituyó en 2012 y tiene su sede en Vancouver, Canadá.
Resumen de fundamentos de AbCellera Biologics Inc.
| Estadísticas fundamentales de ABCL | |
|---|---|
| Capitalización bursátil | US$1.97b |
| Beneficios(TTM) | -US$143.96m |
| Ingresos (TTM) | US$79.21m |
22.4x
Ratio precio-ventas (PS)-12.3x
Ratio precio-beneficio (PE)¿Está ABCL sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de ABCL | |
|---|---|
| Ingresos | US$79.21m |
| Coste de los ingresos | US$191.00m |
| Beneficio bruto | -US$111.79m |
| Otros gastos | US$32.17m |
| Beneficios | -US$143.96m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
Aug 05, 2026
| Beneficios por acción (BPA) | -0.47 |
| Margen bruto | -141.13% |
| Margen de beneficio neto | -181.74% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado ABCL a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/20 05:48 |
| Precio de las acciones al final del día | 2026/07/20 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
AbCellera Biologics Inc. está cubierta por 13 analistas. 8 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Robert Wasserman | Benchmark Company |
| Guyn Kim | BMO Capital Markets Equity Research |
| Evan Seigerman | BMO Capital Markets Equity Research |